Credit Suisse Conference
If you listen to the call from this morning, You find that Lewis is quite bullish and excited about 2020/2021. He expects approval in EU and Japan in the future, as the Key Opinion leaders and government in Japan are looking favorably on Arikayce to help the citizens. Lewis said with new guidelines coming out it would help everyone to know the protocols of determining and treating NTM in the future, which would help Arikayce if they were included. He mentioned that Insmed's drug launch ranked in the Top 10 of all orphan drug launched in the US. He thought the first year was outstanding and all positive, but they are looking to go global and are quite hopeful for frontline therapy going forward.
It is on Insmed's website.